Mumbai — Torrent Pharmaceuticals said Thursday it has voluntarily recalled select batches of its Semalix injection disposable pens as a precaution after manufacturing partner Dr. Reddy’s Laboratories identified a quality issue that requires technical evaluation.
The recall applies only to select batches of Semalix Injection 2 mg and 4 mg manufactured by Dr. Reddy’s Laboratories.
Torrent said the move is precautionary and that there is no risk to patients currently undergoing treatment. The company said patient safety remains its top priority and added that all other semaglutide products in its portfolio are unaffected.
The unaffected products include Semalix tablets in 3 mg, 7 mg and 14 mg strengths; Sembolic tablets in the same strengths manufactured by Torrent; Semalix Injection 8 mg manufactured by MSN Laboratories; and the Sembolic reusable injection manufactured by Zydus Lifesciences.
Torrent advised patients and caregivers with questions about the affected products to contact the company for more information.
Earlier Thursday, Dr. Reddy’s Laboratories told stock exchanges that commercial supplies of semaglutide would be delayed after certain batches were found to be out of specification because of an issue with the active pharmaceutical ingredient used in the product.
The Hyderabad-based drugmaker said it is investigating the root cause and taking corrective measures to ensure product quality. It said commercial supplies will remain on hold until the issue is resolved.
Dr. Reddy’s also said the issue poses no risk to patient safety and does not affect the product’s existing global regulatory filings.
Shares of Torrent Pharmaceuticals closed at Rs 4,896.65 on the BSE, up Rs 29.20, or 0.6 percent. (Source: IANS)
